Gossamer Bio (NASDAQ:GOSS) Coverage Initiated by Analysts at Chardan Capital

Analysts at Chardan Capital started coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a report issued on Tuesday, MarketBeat reports. The firm set a “buy” rating on the stock.

GOSS has been the topic of several other reports. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Finally, Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a report on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Gossamer Bio has a consensus rating of “Hold” and an average price target of $256.00.

Gossamer Bio Trading Up 5.2%

Shares of Gossamer Bio stock traded up $0.48 during trading hours on Tuesday, hitting $9.76. 477,946 shares of the company’s stock traded hands, compared to its average volume of 312,377. The company has a fifty day simple moving average of $12.25 and a 200-day simple moving average of $17.23. Gossamer Bio has a 12-month low of $8.99 and a 12-month high of $309.60.

Institutional Trading of Gossamer Bio

A number of large investors have recently made changes to their positions in GOSS. Rockefeller Capital Management L.P. grew its holdings in Gossamer Bio by 496.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock valued at $189,000 after purchasing an additional 50,666 shares during the period. SG Americas Securities LLC raised its position in shares of Gossamer Bio by 73.4% during the 1st quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock valued at $42,000 after purchasing an additional 54,439 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Gossamer Bio during the 1st quarter valued at $38,000. ADAR1 Capital Management LLC purchased a new stake in shares of Gossamer Bio during the second quarter worth about $35,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in Gossamer Bio by 32.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,098,914 shares of the company’s stock worth $181,000 after purchasing an additional 270,195 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.